bibliographic resource 1309271 [br/1309271]
https://w3id.org/oc/corpus/br/1309271

is a

• document
• article

title

• Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

publication date

• 2011-01-01

contributor

• https://w3id.org/oc/corpus/ar/4422291
• https://w3id.org/oc/corpus/ar/4422292
• https://w3id.org/oc/corpus/ar/4422293
• https://w3id.org/oc/corpus/ar/4422294
• https://w3id.org/oc/corpus/ar/4422295
• https://w3id.org/oc/corpus/ar/4422296
• https://w3id.org/oc/corpus/ar/4422297
• https://w3id.org/oc/corpus/ar/4422298
• https://w3id.org/oc/corpus/ar/4422299
• https://w3id.org/oc/corpus/ar/4422300
• https://w3id.org/oc/corpus/ar/4422301
• https://w3id.org/oc/corpus/ar/4422302

format

• https://w3id.org/oc/corpus/re/627740

identifier

• https://w3id.org/oc/corpus/id/12087294
• https://w3id.org/oc/corpus/id/2273168
• https://w3id.org/oc/corpus/id/2273169
• https://w3id.org/oc/corpus/id/2273170
• https://w3id.org/oc/corpus/id/2273171

part of

• https://w3id.org/oc/corpus/br/478104